Nature Communications (Feb 2023)
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
- James J. Harding,
- Sarina A. Piha-Paul,
- Ronak H. Shah,
- Jessica J. Murphy,
- James M. Cleary,
- Geoffrey I. Shapiro,
- David I. Quinn,
- Irene Braña,
- Victor Moreno,
- Mitesh Borad,
- Sherene Loi,
- Iben Spanggaard,
- Haeseong Park,
- James M. Ford,
- Mónica Arnedos,
- Salomon M. Stemmer,
- Christelle de la Fouchardiere,
- Christos Fountzilas,
- Jie Zhang,
- Daniel DiPrimeo,
- Casey Savin,
- S. Duygu Selcuklu,
- Michael F. Berger,
- Lisa D. Eli,
- Funda Meric-Bernstam,
- Komal Jhaveri,
- David B. Solit,
- Ghassan K. Abou-Alfa
Affiliations
- James J. Harding
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Sarina A. Piha-Paul
- Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center
- Ronak H. Shah
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Jessica J. Murphy
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- James M. Cleary
- Dana-Farber Cancer Institute
- Geoffrey I. Shapiro
- Dana-Farber Cancer Institute
- David I. Quinn
- Keck School of Medicine, USC Norris Cancer Comprehensive Cancer Center
- Irene Braña
- Medical Oncology Department, Vall d’Hebron University Hospital
- Victor Moreno
- START MADRID-FJD, Hospital Fundación Jiménez Díaz
- Mitesh Borad
- Medical Oncology Department, Mayo Clinic
- Sherene Loi
- Translational Breast Cancer Genomics and Therapeutics Laboratory, Peter MacCallum Cancer Centre
- Iben Spanggaard
- Department of Oncology, Rigshospitalet, Copenhagen University Hospital
- Haeseong Park
- Division of Oncology, Washington University School of Medicine in St. Louis
- James M. Ford
- Department of Medicine (Oncology), Stanford Cancer Institute
- Mónica Arnedos
- Medical Oncology Department, Gustave Roussy, Villejuif, France (currently at: Institut Bergonie
- Salomon M. Stemmer
- Institute of Oncology, Davidoff Center, Rabin Medical Center
- Christelle de la Fouchardiere
- Medical Oncology Department, Centre Léon Bérard
- Christos Fountzilas
- Division of GI Medicine, Department of Medicine, Roswell Park Comprehensive Cancer Center
- Jie Zhang
- Translational Medicine and Diagnostics, Puma Biotechnology Inc
- Daniel DiPrimeo
- Translational Medicine and Diagnostics, Puma Biotechnology Inc
- Casey Savin
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- S. Duygu Selcuklu
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Michael F. Berger
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Lisa D. Eli
- Translational Medicine and Diagnostics, Puma Biotechnology Inc
- Funda Meric-Bernstam
- Department of Investigational Cancer Therapeutics, The University of Texas, MD Anderson Cancer Center
- Komal Jhaveri
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- David B. Solit
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- Ghassan K. Abou-Alfa
- Department of Medicine, Memorial Sloan Kettering Cancer Center
- DOI
- https://doi.org/10.1038/s41467-023-36399-y
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 12
Abstract
In biliary tract cancer HER2 alterations correlate with poor prognosis. Here, the authors present the results of a phase II clinical trial reporting the efficacy and safety of the tyrosine kinase inhibitor neratinib in patients with HER2-mutation positive advanced biliary tract cancers.
